CRISPR Therapeutics

CRSP

Market cap $6.22B

Investing in modestly sized growth stocks can lead to significant returns, but oftentimes it requires taking on a fair bit of risk and being willing to wait at least a few years for a payoff. There are, however, ways to reduce your risk, such as by targeting stocks with good financials and that already have approved products with a lot of potential.

Most investors probably step into a stock with the intent of holding on to it indefinitely (as long as nothing significant changes, and it continues to perform well). Sometimes, though, new technologies put a company and its stock in a position to shine brilliantly for only a few years.

Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research pipelines advanced.

-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile-

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving 2.46% from the previous trading session.

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices of certain drugs in the U.S. and investing in local manufacturing efforts. This deal lifted not only Pfizer, but also much of the healthcare sector, especially the company's drugmaking peers, as Wall Street expects more deals along those lines.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics AG (CRSP) reached $67.74 at the closing of the latest trading day, reflecting a -6.98% change compared to its last close.

ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress, taking place October 7-10, 2025. The presentation will introduce the Company's novel SyNTase gene editing technology and highlight its application in single-dose in vivo gene correction to treat Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder.